The drug named Mycidac-C is competitively priced at Rs 40,000 for a 10-course injection. It is much cheaper than other similar drugs in the market, which could help take the drug global.
Cadila Pharma is hoping to make lung cancer treatment more affordable with the launch of its new drug this month. The drug named Mycidac-C is competitively priced at Rs 40,000 for a 10-course injection. It is much cheaper than other similar drugs in the market, which could help take the drug global.
Rajiv Modi, chairman and managing director of Cadila Pharma has his hands full. While preparing for the launch of Cadila's latest research and development (R&D) success - its non-small cell lung cancer drug - the Mycidac-C, Modi is simultaneously working on taking it global. After spending over a Rs 100 crore on developing the novel drug, the company is now aiming to launch the drug in South East Asia, Africa and Latin America. Cadila is also on the look out for a suitable oncology partner to introduce the drug in developed markets. Rajiv Modi, cmd of Cadila Pharma says we have completely de-risked the product and have conducted a fairly large clinical trial in India. But for making regulatory submissions in large markets like US, EU, Japan we are looking for a global oncology player who has more experience and expertise to take forward the global clinical trials and filings for this drug. He adds, “The first target of course is the Indian market.” India has nearly 50,000 new cases of lung cancer every year and Cadila hopes the competitively priced Mycidac-C, which is available at almost one-tenth the cost of existing therapies will be able to make a dent in the Rs 300 crore market for lung cancer drugs. “We have priced Mycidac-C at Rs.40,000 for a full course of 10 injections required during chemotherapy,” says Modi. With Cadila ready for the launch of the drug in India this month, the company says it is now progressing on its existing R&D pipeline to hunt for more novel drugs in the area of vaccines, infectious diseases and gastro-enterology.
Source: http://www.moneycontrol.com/news/cnbc-tv18-comments/cadila-to-launch-new-affordable-lung-cancer-drug-soon_1000841.html
Cadila Pharma is hoping to make lung cancer treatment more affordable with the launch of its new drug this month. The drug named Mycidac-C is competitively priced at Rs 40,000 for a 10-course injection. It is much cheaper than other similar drugs in the market, which could help take the drug global.
Rajiv Modi, chairman and managing director of Cadila Pharma has his hands full. While preparing for the launch of Cadila's latest research and development (R&D) success - its non-small cell lung cancer drug - the Mycidac-C, Modi is simultaneously working on taking it global. After spending over a Rs 100 crore on developing the novel drug, the company is now aiming to launch the drug in South East Asia, Africa and Latin America. Cadila is also on the look out for a suitable oncology partner to introduce the drug in developed markets. Rajiv Modi, cmd of Cadila Pharma says we have completely de-risked the product and have conducted a fairly large clinical trial in India. But for making regulatory submissions in large markets like US, EU, Japan we are looking for a global oncology player who has more experience and expertise to take forward the global clinical trials and filings for this drug. He adds, “The first target of course is the Indian market.” India has nearly 50,000 new cases of lung cancer every year and Cadila hopes the competitively priced Mycidac-C, which is available at almost one-tenth the cost of existing therapies will be able to make a dent in the Rs 300 crore market for lung cancer drugs. “We have priced Mycidac-C at Rs.40,000 for a full course of 10 injections required during chemotherapy,” says Modi. With Cadila ready for the launch of the drug in India this month, the company says it is now progressing on its existing R&D pipeline to hunt for more novel drugs in the area of vaccines, infectious diseases and gastro-enterology.
Source: http://www.moneycontrol.com/news/cnbc-tv18-comments/cadila-to-launch-new-affordable-lung-cancer-drug-soon_1000841.html
No comments:
Post a Comment